Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
about
The potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaThe biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemiaApplications of chemogenomic library screening in drug discoveryCD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cellsEliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.Chronic lymphocytic leukemia therapy: new targeted therapies on the wayHigh-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cellsDimethyl celecoxib sensitizes gastric cancer cells to ABT-737 via AIF nuclear translocation.Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.Development of venetoclax for therapy of lymphoid malignancies.Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies.Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).Targeting of B-cell receptor signalling in B-cell malignancies.The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.To Prime, or Not to Prime: That Is the Question.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Venetoclax: First Global Approval.Recent advances in therapy of chronic lymphocytic leukaemia.Magic pills: new oral drugs to treat chronic lymphocytic leukemia.Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell MalignanciesBruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia.Chronic lymphocytic leukaemia genomics and the precision medicine era.Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment.BCL2/Ki-67 index predict survival in germinal center B-cell-like diffuse large B-cell lymphoma.Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells.Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemiaThe Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax.Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.Recent therapeutic advances in chronic lymphocytic leukemia.Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
P2860
Q28075504-1797559E-C6C0-42B2-AEE8-93049BB7EC6AQ28075683-D56E4E40-F6CA-4D43-84E2-F520AFA866A4Q28656335-63509E80-B6A8-4AD3-9453-E60D65524456Q30383411-4DA4C3F6-1370-46FC-BADE-3AB9CA117347Q36746585-ACB9EFDD-337D-42B4-AAF2-2EDC7E978DF0Q36788133-205E8C86-8304-4EF4-8897-C4E7F3C31A2DQ37035832-3FF60566-8A74-4081-BF26-D319C515870DQ37113544-9879D010-AF4C-49E1-B609-7EC5A80BA14DQ37209768-BC2C3CB8-7659-4B2B-A5C0-48B4BAEC5934Q37370784-63A294DE-989C-4007-9719-17FB7CC190B8Q37688589-4DAFA768-1236-4F1C-8A9C-37416D4E42E9Q37702281-5539E66C-2565-4881-AA5A-C521C569660BQ37725415-9E233346-5115-4A4D-BFFF-6D5A30D5EA95Q38637652-512C4A11-2A48-480A-9C80-58846FB591C6Q38722012-F4337C4E-DE50-4CF8-BB4D-98FE989D36EAQ38739050-009F3F48-05CF-4891-8B11-8841A734D347Q38744922-7887C724-8507-4037-AF44-510336167437Q38766548-FA0603EC-D41B-4830-ACC9-34103805FB95Q38798849-5953F9A6-8392-4ECA-AD16-F592E3C37266Q38818283-5399BD7C-C65C-4017-9DC1-DB859E6BB12EQ38853500-87BDE338-293A-4E51-9E06-813A045D82CEQ38862525-50A97263-E3C3-4D8A-A84A-7DB57FB1591CQ38943877-2A6DDE7A-F467-4FE5-9E47-333BA44A7B76Q38996888-726BC658-60AC-4385-A28B-78DF4F40CEF4Q39006397-C7E8E0EA-BB58-4A0B-A8D1-21D582BD3571Q39065374-2177897C-46CF-4236-8592-D0FE8EF37AADQ39145934-26F88456-1DC0-4007-AA56-2F318450627CQ39263974-8F0054C4-B693-4050-B8C0-0AC07311B565Q39325783-8CE0E176-E79D-42F0-BE18-1C71472C47D9Q41070355-8F5F03C0-F143-4379-9FE7-5C1CE77B75C9Q41615108-A22E5321-87D7-4BB9-8D85-38F123FF0B27Q41652556-1F30F16A-F00D-462F-A437-207E124C3BA5Q41848521-DF585E21-721A-44E9-AEA2-1675510D9576Q41865162-8C6FF294-6783-44B2-843F-4A2905C1294EQ43090573-FA5E4ED7-DDA8-4919-AC27-33467DBF2120Q44633375-A001CBCD-6BB2-4993-9F00-22C33B431CACQ46055970-ADC0E936-3FDF-43CF-8F97-6E311D7DDE97Q46318389-51978D4E-8FCF-4D3B-96A8-571E7798B2ADQ46370948-B82FCF16-4CD5-4663-8EEF-2FE0274AAAFFQ47136959-0C616BF0-73F8-45D4-B715-DBD0A762640E
P2860
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pharmacological and Protein Pr ...... n Chronic Lymphocytic Leukemia
@ast
Pharmacological and Protein Pr ...... n Chronic Lymphocytic Leukemia
@en
type
label
Pharmacological and Protein Pr ...... n Chronic Lymphocytic Leukemia
@ast
Pharmacological and Protein Pr ...... n Chronic Lymphocytic Leukemia
@en
prefLabel
Pharmacological and Protein Pr ...... n Chronic Lymphocytic Leukemia
@ast
Pharmacological and Protein Pr ...... n Chronic Lymphocytic Leukemia
@en
P2093
P2860
P921
P1476
Pharmacological and Protein Pr ...... n Chronic Lymphocytic Leukemia
@en
P2093
Betty Lamothe
Fabiola Cervantes-Gomez
Jennifer A Woyach
Kumudha Balakrishnan
Varsha Gandhi
P2860
P304
P356
10.1158/1078-0432.CCR-14-2809
P407
P577
2015-03-31T00:00:00Z